Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that […] The post Presentations highlight efzofitimod’s potential for pulmonary sarcoidosis appeared first on Sarcoidosis News.| Sarcoidosis News – The Web's Daily Resource for Sarcoidosis News
The findings of a new preclinical study in pulmonary sarcoidosis are lending support to the therapeutic potential of efzofitimod, a treatment candidate from Atyr Pharma now being tested in a Phase […] The post Study backs efzofitimod as potential pulmonary sarcoidosis treatment appeared first on Sarcoidosis News.| Sarcoidosis News – The Web's Daily Resource for Sarcoidosis News
The safety and tolerability is being tested of two XTMAB-16 doses against a placebo in patients on a stable corticosteroid dose.| Sarcoidosis News